Predictive factors of a viral neutralizing humoral response after a third dose of COVID-19 mRNA vaccine

Kidney transplant recipients (KTRs) have reduced ability to mount adequate antibody response after two doses of the COVID‐19 mRNA vaccine. French health authorities have allowed a third booster dose (D3) for KTRs, but their response is heterogeneous and tools able to discriminate the responders are lacking.

[1]  K. Stiasny,et al.  Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial , 2021, Annals of the Rheumatic Diseases.

[2]  T. Harrer,et al.  Efficacy and safety of SARS-CoV-2 revaccination in non-responders with immune-mediated inflammatory disease , 2021, Annals of the Rheumatic Diseases.

[3]  L. Juillard,et al.  A prospective observational study for justification, safety, and efficacy of a third dose of mRNA vaccine in patients receiving maintenance hemodialysis , 2021, Kidney International.

[4]  R. Baric,et al.  Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines , 2021, The New England journal of medicine.

[5]  M. Gui,et al.  Humoral and cellular immune response to severe acute respiratory syndrome coronavirus‐2 vaccination in haemodialysis and kidney transplant patients , 2021, Nephrology.

[6]  G. Tomlinson,et al.  Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients , 2021, The New England journal of medicine.

[7]  S. Fafi-Kremer,et al.  Comparison of infected and vaccinated transplant recipients highlights the role of Tfh and neutralizing IgG in COVID-19 protection , 2021, medRxiv.

[8]  S. Fafi-Kremer,et al.  Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses. , 2021, JAMA.

[9]  T. Tonn,et al.  Cellular and Humoral Immune Responses After 3 Doses of BNT162b2 mRNA SARS-CoV-2 Vaccine in Kidney Transplant , 2021, Transplantation.

[10]  J. Vekemans,et al.  Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection , 2021, Nature Medicine.

[11]  J. Izopet,et al.  Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients , 2021, The New England journal of medicine.

[12]  J. Achard,et al.  Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients , 2021, Journal of the American Society of Nephrology : JASN.

[13]  A. Sattler,et al.  Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. , 2021, Science immunology.

[14]  D. Segev,et al.  Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series , 2021, Annals of Internal Medicine.

[15]  F. Lund-Johansen,et al.  Low Immunization Rate in Kidney Transplant Recipients Also After Dose 2 of the BNT162b2 Vaccine: Continue to Keep Your Guard up! , 2021, Transplantation.

[16]  N. Kamar,et al.  Occurrence of severe COVID-19 in vaccinated transplant patients , 2021, Kidney International.

[17]  M. Davenport,et al.  Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.

[18]  A. Kribben,et al.  Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech) , 2021, Viruses.

[19]  L. Braun-Parvez,et al.  Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine , 2021, Kidney International.

[20]  D. Schwartz,et al.  Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus , 2021, American Journal of Transplantation.

[21]  J. Izopet,et al.  Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated with Belatacept. , 2021, Transplantation.

[22]  C. Conrad,et al.  Impaired Humoral and Cellular Immunity after SARS-CoV2 BNT162b2 (Tozinameran) Prime-Boost Vaccination in Kidney Transplant Recipients , 2021, medRxiv.

[23]  C. Giaquinto,et al.  Analytical and clinical performances of a SARS-CoV-2 S-RBD IgG assay: comparison with neutralization titers , 2021, Clinical chemistry and laboratory medicine.

[24]  E. Hod,et al.  Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum , 2020, Nature Immunology.

[25]  J. Dumortier,et al.  IMPact of the COVID-19 epidemic on the moRTAlity of kidney transplant recipients and candidates in a French Nationwide registry sTudy (IMPORTANT) , 2020, Kidney International.

[26]  C. Wanner,et al.  Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe , 2020, Kidney International.

[27]  J. Dumortier,et al.  An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants , 2020, Kidney International.

[28]  K. Bhaskaran,et al.  Factors associated with COVID-19-related death using OpenSAFELY , 2020, Nature.

[29]  A. Hashem,et al.  Evaluation of MERS-CoV Neutralizing Antibodies in Sera Using Live Virus Microneutralization Assay , 2019, Methods in molecular biology.

[30]  N. Pallet,et al.  Residual Activatability of Circulating Tfh17 Predicts Humoral Response to Thymodependent Antigens in Patients on Therapeutic Immunosuppression , 2019, Front. Immunol..

[31]  M. Ovize,et al.  CD4+ T Cell Help Is Mandatory for Naive and Memory Donor-Specific Antibody Responses: Impact of Therapeutic Immunosuppression , 2018, Front. Immunol..

[32]  A. Šimundić,et al.  Clinical Chemistry and Laboratory Medicine CCLM , 2017 .